Skip to main content
Premium Trial:

Request an Annual Quote

UK's Institute of Cancer Research Taps Dotmatics' Software for Drug Discovery Work

Premium

Dotmatics said this week that the Institute of Cancer Research, London, has licensed Vortex, its data visualization and analysis tool, for use in cancer drug research and development efforts.

Julian Blagg, who heads ICR’s chemistry department and is the deputy director of its cancer therapeutics division, said that the institute selected Vortex, after internal testing, because of its "flexibility, ease of use and swift integration with our existing chemoinformatics data storage platform.”

The financial details of the licensing agreement were not disclosed.

Another oncology-focused client of Dotmatics is Cancer Therapeutics CRC, a small-molecule drug discovery company based in Bundoora, Australia.

The company uses Dotmatics’ platform to query and analyze data from cancer pathways associated with the tumor microenvironment or growth in breast, prostate, melanoma, lung, and brain cancers (BI 6/8/2012).

The Scan

Unwrapping Mummies' Faces

LiveScience reports that Parabon NanoLabs researchers have reconstructed how three Egyptian mummies may have looked.

Study on Hold

The Spectrum 10K study has been put on hold due to a backlash, leading the researchers to conduct consultations with the autism community, Nature News reports.

Others Out There Already

Reuters reports that Sanofi is no longer developing an mRNA-based vaccine for SARS-CoV-2.

PNAS Papers on GWAS False Discovery, PRAMEF2 Role in Tumorigenesis, RNA Virus Reverse Genetics

In PNAS this week: strategy to account for GWAS false-discovery rates, role of PRAMEF2 in cancer development, and more.